Prelude Capital Management, LLC Sellas Life Sciences Group, Inc. Transaction History
Prelude Capital Management, LLC
- $1.57 Billion
- Q3 2024
A detailed history of Prelude Capital Management, LLC transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 58,338 shares of SLS stock, worth $59,504. This represents 0.0% of its overall portfolio holdings.
Number of Shares
58,338
Previous 58,338
-0.0%
Holding current value
$59,504
Previous $72,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding SLS
# of Institutions
39Shares Held
5.69MCall Options Held
1.67MPut Options Held
74.7K-
Vanguard Group Inc Valley Forge, PA2.29MShares$2.34 Million0.0% of portfolio
-
Anson Funds Management LP Dallas, TX794KShares$809,7110.12% of portfolio
-
Geode Capital Management, LLC Boston, MA605KShares$617,2940.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$438,9750.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$314,6353.71% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $21M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...